HK Ascent

Ascentage Pharma is a global clinical-stage biotechnology company focused on developing novel therapies for cancers, hepatitis B virus (HBV), and age-related diseases. The company specializes in the development of small-molecule drugs that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in diseased cells. Its lead product, olverembatinib (HQP1351), is a third-generation BCR-ABL inhibitor approved in China for the treatment of drug-resistant chronic myeloid leukemia. Ascentage maintains a robust pipeline of candidates targeting key apoptotic pathways, including BCL-2, BCL-XL, and MDM2-p53, with several programs in global Phase 1 and 2 clinical trials. Headquartered in Suzhou, China, and listed on the Hong Kong Stock Exchange, the company operates R&D centers and clinical development facilities in both China and the United States.